



ASX & MEDIA RELEASE

10 NOVEMBER 2016

BREAKTHROUGH FOR MEDLAB, DEPT OF HEALTH (TGA) GRANTS LICENCE FOR CANNABIS

Medical life science company, Medlab Clinical Limited (ASX: MDC), has received a licence to import cannabis from the Australian Department of Health/Therapeutic Goods Administration (TGA).

For Medlab this is a critical step towards commencing a clinical trial using cannabis for patients suffering intractable cancer pain and represents a validation of Medlab's pathway to pain management medication.

Medlab Managing Director, Mr Sean Hall, said this was a significant milestone for Medlab.

"It shows we have satisfied TGA requirements, allowing the import of a proprietary liquid cannabis blend which will be used in our clinical trial," Mr Hall said.

"It also means we can look at starting manufacture of NanoCelle™ Cannabis, which we've named Nanabis™ and which will be the delivery mechanism for administering our cannabis formulation in nano-sized particles by mouth.

"With the TGA approval and this being advised to Royal North Shore Hospital, we are entering the final stages of meeting requirements for ethics approval for the clinical trial.

"Ethics approval and ultimate issue of a clinical trial number from TGA are final pre-requisites for the trial to begin, but with cannabis import approval achieved, indications are the trial should begin earlier than previously indicated, and hopefully this year," Mr Hall said.

Medlab will import the proprietary cannabis blend from Canada, through a licenced producer of medical marijuana, Aphria Inc. (TSX-V: APH, OTCQB: APHQF), completing the final product at a specialised pharmaceutical facility in Melbourne.

Cannabis plant species, yields and a novel extraction process have been established in collaboration between Medlab and Aphria, allowing Aphria to produce large scale supply for Medlab.

Medlab's clinical trials at Royal North Shore Hospital in Sydney, will be supervised by Professor Stephen Clarke OAM, a medical oncologist, palliative medicine specialist and Professor of Medicine at the University of Sydney.

Recent statistics regarding cancer pain indicate it is prevalent in 64 per cent of patients with metastatic or advanced stage disease and that for one in two patients with cancer, it is undertreated.

Mr Hall said this was a major pillar in Medlab's research and development of its pain management portfolio.

ISSUED FOR: MEDLAB CLINICAL LTD (ASX: MDC) – www.medlab.co

FOR FURTHER INFORMATION: MR SEAN HALL, CEO, MEDLAB CLINICAL
TEL: +61 2 8203 9520, sean_hall@medlab.co

ISSUED BY: HILL + KNOWLTON STRATEGIES, MARCHA VAN DEN HEUVEL
TEL +61 2 9286 1226 OR +61 468 960 457, marcha.vandenheuvel@hkstrategies.com

ABOUT MEDLAB – www.medlab.co

Medlab Clinical is an Australian based biotechnology company, with a certified biologics facility in Sydney and sales arms in Australia and California. Medlab's research focuses on five health areas: obesity, chronic kidney disease, depression, ageing and muscular skeletal health and pain management. Medlab develops and sells nutraceuticals in the US and Australia to support drug discovery and development of new medicines. Medlab has a growing patent portfolio, multiple published research papers and conference presentations and the Pharmacobiotic trademark – a therapeutic term referring to both probiotics and biologics.